Cyteir Therapeutics
Developing the next generation of synthetic lethal therapies to treat cancer.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | $133m Valuation: $620m -14.7x EV/EBITDA | IPO | |
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Cyteir Therapeutics is a pioneering biotechnology company focused on developing novel therapeutics for cancer treatment through the biology of DNA repair and synthetic lethality. The company operates in the oncology market, primarily serving patients with various types of cancer. Cyteir's business model revolves around the discovery and development of drugs that induce selective self-destruction of cancer cells by targeting disease-induced RAD51 activity, leading to DNA damage overload. Revenue is generated through the development and commercialization of these specialized cancer therapies, as well as potential partnerships and licensing agreements with larger pharmaceutical companies.
Keywords: synthetic lethality, DNA repair, cancer treatment, oncology, RAD51 targeting, biotechnology, novel therapeutics, drug development, precision medicine, cancer therapies.